|
5 Companies |
|
0 Products |
|
0 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
27 News |
|
- | Trial completion, Trial primary completion date: NCCLS Interpretive Criteria for Salmonella (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=50, Completed, Sponsor: University of Pittsburgh
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2016 --> Jun 2017
- Trial completion: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=1927, Completed, Sponsor: University Hospital, Geneva
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed
- Trial completion, Enrollment change: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=2800, Completed, Sponsor: Swiss Tropical & Public Health Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=4000 --> 2800
- Gatiflox (gatifloxacin) / Orient Europharma
Trial completion, Head-to-Head: Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) - Oct 4, 2016
P4, N=300, Completed, Sponsor: Oxford University Clinical Research Unit, Vietnam
Active, not recruiting --> Completed | N=4000 --> 2800 Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=4000, Active, not recruiting, Sponsor: Swiss Tropical & Public Health Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- Enrollment open: NCCLS Interpretive Criteria for Salmonella (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=50, Enrolling by invitation, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Enrolling by invitation
- Enrollment closed: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=1927, Active, not recruiting, Sponsor: University Hospital, Geneva
Active, not recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- Enrollment open, Trial initiation date: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=4000, Recruiting, Sponsor: Swiss Tropical & Public Health Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014
- Gatiflox (gatifloxacin) / Orient Europharma
Enrollment closed, Head-to-Head: Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) - Jul 16, 2014
P4, N=300, Active, not recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - May 12, 2014
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2014 --> Dec 2014
- Trial completion date: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - May 12, 2014
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Trial primary completion date: Feb 2014 --> Dec 2014 Trial completion date: May 2014 --> Dec 2014
- Clinical: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Apr 3, 2014
P=N/A, N=4000, Not yet recruiting, Sponsor: Swiss Tropical & Public Health Institute
- |||| NN1213 / Novo Nordisk, Havrix (hepatitis A vaccine, inactivated) / GSK
Trial completion: Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood (clinicaltrials.gov) - Feb 22, 2014
P4, N=27231, Completed, Sponsor: International Vaccine Institute
Trial completion date: May 2014 --> Dec 2014 No longer recruiting --> Completed
- |||| NN1213 / Novo Nordisk, Havrix (hepatitis A vaccine, inactivated) / GSK
Trial completion: Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever (clinicaltrials.gov) - Feb 22, 2014
P4, N=37673, Completed, Sponsor: International Vaccine Institute
No longer recruiting --> Completed No longer recruiting --> Completed
- Enrollment open: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion: Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects (clinicaltrials.gov) - Jan 21, 2013
P3, N=200, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) - Sep 18, 2012
P2, N=120, Completed, Sponsor: Novartis
Recruiting --> Completed Active, not recruiting --> Completed
- |||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (clinicaltrials.gov) - Sep 18, 2012
P2, N=200, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: NCCLS Interpretive Criteria for Salmonella (clinicaltrials.gov) - Aug 22, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
New P3 trial: Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects (clinicaltrials.gov) - May 29, 2012
P3, N=200, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- |||| Trial completion: Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (clinicaltrials.gov) - Jan 8, 2012
P2, N=51, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) - Dec 8, 2011
P2, N=120, Completed, Sponsor: Novartis
Active, not recruiting --> Completed N=80 --> 120
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (clinicaltrials.gov) - Nov 27, 2011
P2, N=200, Completed, Sponsor: Novartis
N=80 --> 120 N=320 --> 200
- ||||| New P2 trial: Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (clinicaltrials.gov) - Sep 18, 2011
P2, N=51, Completed, Sponsor: Novartis
- ||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P2 trial: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) - Sep 18, 2011
P2, N=120, Completed, Sponsor: Novartis
- Gatiflox (gatifloxacin) / Orient Europharma
Enrollment open, Head-to-Head: Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) - Sep 18, 2011
P4, N=300, Recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam
N=320 --> 200 Not yet recruiting --> Recruiting
- | Gatiflox (gatifloxacin) / Orient Europharma
New P4 trial, Head-to-Head: Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) - Aug 21, 2011
P4, N=300, Recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam